CliffBio
small molecule

MOMETASONE FUROATE

MOMETASONE FUROATE

Loss of exclusivity—loss of exclusivity
CompanyCosette Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameMOMETASONE FUROATE
Active ingredientMOMETASONE FUROATE
Strength0.1%
Dosage formLOTION
RouteTOPICAL
ModalitySmall molecule
FDA approvalNovember 2007
Marketing statusDISCN

More from Cosette Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.